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Abstract
Background: Coronavirus-19 (COVID-19) has been declared a global pandemic by the World Health Organisation.
Severe disease typically presents with respiratory failure but Acute Kidney Injury (AKI) and a hypercoagulable state
can also occur. Early reports suggest that thrombosis may be linked with AKI. We studied the development of AKI
and outcomes of patients with COVID-19 taking chronic anticoagulation therapy.
Methods: Electronic records were reviewed for all adult patients admitted to Manchester University Foundation
Trust Hospitals between March 10 and April 302,020 with a diagnosis of COVID-19. Patients with end-stage kidney
disease were excluded. AKI was classified as per KDIGO criteria.
Results: Of the 1032 patients with COVID-19 studied,164 (15.9%) were taking anticoagulant therapy prior to
admission. There were similar rates of AKI between those on anticoagulants and those not anticoagulated (23.8% versus
19.7%) with no difference in the severity of AKI or requirement of renal replacement therapy between groups (1.2%
versus 3.5%). Risk factors for AKI included hypertension, pre-existing renal disease and male sex. There was a higher
mortality in those taking anticoagulant therapy (40.2% versus 30%). Patients taking anticoagulants were less likely to be
admitted to the Intensive Care Unit (8.5% versus 17.4%) and to receive mechanical ventilation (42.9% versus 78.1%).
Conclusion: Patients on chronic anticoagulant therapy did not have a reduced incidence or severity of AKI suggesting
that AKI is unlikely to be thrombotic in nature. Therapeutic anticoagulation is currently still under investigation in
randomised controlled studies to determine whether it has a potential role in COVID-19 treatment.
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Background
The World Health Organisation (WHO) declared the
novel coronavirus 19 disease (COVID-19) a global pan-
demic in March 2020 [1]. The majority of patients with
COVID-19 suffer mild symptoms and do not require
hospital admission. More severe disease typically presents
with dyspnoea and acute respiratory failure. In addition to
respiratory issues, severe COVID-19 has been linked to
cardiovascular complications such as myocardial infarc-
tion and acute stroke as well as acute kidney injury (AKI)
[2, 3]. A hypercoagulable state is characteristic of severe
COVID-19, with marked elevations of fibrinogen, factor
VIII, and D-dimer [4, 5], and high rates of venous
thromboembolism (including pulmonary embolism). Pa-
tients critically ill due to COVID-19 have been reported to
have thrombotic event rates in the range of 20–30% in
studies from the Netherlands, Italy and France, despite the
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use of venous thromboembolism (VTE) prophylaxis [6–8].
These are somewhat higher than seen in non-COVID crit-
ically ill patients where VTE rates are reported around 6%
despite prophylaxis [7, 9]. The thrombotic process has
been suggested to start prior to hospitalization, with Lodi-
giani et al. identifying 50% of VTE events within 24 h of
admission [8].
Although original reports from Wuhan suggested rates
of AKI were relatively low at around 5% [10] further
analyses showed much higher rates of AKI associated
with severe COVID-19, reported in 40–75% of intensive
care unit (ICU) patients in Europe and the USA [11–13].
AKI is also considered a negative prognostic factor for
survival [10, 14, 15]. Multiple mechanisms have been
proposed for AKI including ischaemic acute tubular
necrosis secondary to vascular collapse, endothelial dam-
age, casts secondary to rhabdomyolysis and coagulopa-
thy [16–18]. Post-mortem studies from China and New
York support renal microvascular thrombosis as a po-
tential cause of AKI [19–21].
There is the potential that the kidney may be a target
for direct virus-mediated injury from SARS-CoV-2 via
its ACE2 protein [16]. Direct viral microvascular injury
exposes the subendothelial matrix containing tissue fac-
tor (TF) and collagen [22]. This contributes to activation
of platelets and the coagulation cascade leading to fibrin
formation and local thrombosis. The TF released during
endothelial cell damage also leads to activation of inflam-
matory mediators such as C-Reactive protein (CRP) and
Interleukin 6 (IL-6). Increased IL-6 levels are associated
with increased plasma fibrinogen [20] and inflammatory
mediator release results in increased TF expression further
enhancing the hypercoagulable state [22, 23].
If AKI is related to COVID-19 thrombosis and the
thrombotic process has begun prior to hospitalisation it
may be conceived that patients on chronic anticoagulant
therapy would have a reduced risk of developing AKI.
With AKI associated with both poorer survival and ICU
requirement for renal replacement therapy (RRT) [10–
12, 17] chronic anticoagulation may also provide add-
itional benefits. This study identified all COVID-19 posi-
tive patients admitted to Manchester University NHS
Foundation trust, one of the largest hospitals trusts in
the North West of England, who were receiving anti-
coagulant therapy at least 1 month prior to admission.
The aim was to identify if chronic anticoagulant therapy
had any effect on the incidence and severity of AKI to
shed light on whether thrombosis may play a role in
AKI aetiology in those with COVID-19.
Methods
This study is a retrospective review of all hospital admis-
sions with laboratory confirmed COVID 19 across a
large NHS trust from 1st March 2020 to 30th April 2020
inclusive. All adult patients admitted to Manchester
University NHS Foundation trust, aged > 18 years, were
included if they had a positive polymerase chain reaction
test of the nasopharyngeal or lower respiratory tract for
COVID-19. All day cases and known haemodialysis pa-
tients were excluded.
Setting
The setting for this study was in the leading provider of
tertiary and specialist healthcare services in Greater
Manchester, Manchester University NHS Foundation
Trust (MFT) Hospitals. It comprises 10 hospitals/man-
aged clinical services across six separate sites, providing
a wide range of services from comprehensive local gen-
eral hospital care through to highly specialised regional
and national services.
Electronic hospital records were used to collect demo-
graphic and co-morbidity data. Patients were followed
up for 30 days following COVID-19 diagnosis. Anti-
coagulant status on admission was determined using
hospital records including letters, discharge summaries
and General Practitioner (GP) records. Patients were in-
cluded if they had been taking the anticoagulant for
more than 1month and this was confirmed manually
with medication issues.
Acute kidney injury
Serum creatinine values were used to identify AKI de-
fined according to Kidney Disease Improving Global
Outcomes (KDIGO) criteria [15] as follows: stage 1—in-
crease in serum creatinine by 26.5micromol/L within 48
h or a 1.5 to 1.9 times increase in serum creatinine from
baseline within 7 days; stage 2—2.9 times increase in
serum creatinine within 7 days; stage 3—3 times or more
increase in serum creatinine within 7 days or initiation
of RRT. Although an electronic AKI detection and alert-
ing system has already been in place within the trust
since March 2016 (Think Kidneys/NPSA Safety Alert
NHS/PSA/RE/2016/007), manual confirmation of each
AKI case was still carried out, to ensure a valid baseline
creatinine result was utilised. Community acquired-AKI
was defined as AKI present within 24 h of hospital ad-
mission. All in-patients who had AKI from 7 days prior
to COVID positive date and after the positive result date
were included. In the period March 2020 to May 2020
routine screening for COVID-19 was not undertaken on
all patients admitted to Manchester University NHS
Foundation trust unless they presented with cough or
respiratory symptoms. It may have been the case that
some patients had asymptomatic COVID-19 on admis-
sion but not presented with symptoms for up to 7 days
after hospitalisation [24]. Any patients who had devel-
oped AKI and recovered 7 days prior to the COVID
positive date were excluded. Urine output criteria to
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define AKI were not utilised due to documentation be-
ing unreliable. Patients without a baseline creatinine
were deemed to have AKI if they required renal replace-
ment therapy as per KDIGO criteria or were deemed as
clinical AKI based on manual review of consecutive cre-
atinine results.
Blood results
Baseline blood results were the results on day 0 (day of
the first positive COVID sample) and if no blood tests
on that day then the sample nearest to the day 0 result
(no greater than 7 days earlier were used).
Physiological observations
Patientrack™ by Alcidion is an electronic clinical obser-
vation system which is used to collect the observations
at the bedside of patients across MFT. Observation data
(temperature, blood pressure, mean arterial pressure
(MAP), respiratory rate, oxygen saturations and early
warning score (EWS)) for the patient cohort was col-
lected and the set of observations closest to the COVID-
19 positive date was considered.
All methods were carried out in accordance with rele-
vant guidelines and regulations.
The primary endpoint was to identify if chronic anti-
coagulant therapy had any effect on the incidence and
severity of AKI. Secondary endpoints included informa-
tion on mortality, admission to critical care and require-
ment of mechanical ventilation.
Statistical analysis
Categorical variables are presented as number and per-
centage. Normality was assessed using the Shapiro-Wilk
normality test. Non-parametric continuous variables are
presented throughout as the median and interquartile
range. Univariable and multivariable logistic regression
was used to assess factors predicting the development of
AKI. The multivariable model is based on factors
deemed to be clinically relevant such as demographics,
and those factors which were found to be significant in
the univariable logistic regression. Post-analysis good-
ness of fit was assessed using Akaike information criter-
ion (AIC), c-statistic and the Hosmer-Lemeshow test.
Survival analysis was carried out using a Cox propor-
tional regression model. The multivariable model was
adjusted for demographics and variables showing signifi-
cance at univariable analysis. A p-value less than 0.05
was considered statistically significant throughout and
all analysis was carried out using R version 3.6.122.
Results
Demographics
From March 1, 2020 to April 30, 2020, a total of 11,721
patients were admitted to MFT hospitals with 1166 of
these having a diagnosis of COVID-19. After excluding
the 35 dialysis patients and 99 day cases, there were a
total of 1032 COVID-19 positive patients included in the
analysis. Of these there were 164 patients (15.9%) taking
anticoagulants for a minimum of 1 month prior to ad-
mission. Overall the anticoagulated patients were signifi-
cantly older 80 versus 68 years (p < 0.001), had a higher
Charlson Comorbidity Index (CCI) 2 versus 1 (p < 0.001)
and were more likely to have hypertension (HTN) (p =
0.042), renal impairment (p = 0.009), cancer (p = 0.004)
and heart failure (p < 0.001) (Table 1). Patients taking
anticoagulants were more likely to be of white race, 139
(84.8%) versus 586 (67.6%) of those not anticoagulated
(p < 0.001).
Anticoagulant therapy
The most common anticoagulant therapy was the Direct
Acting Oral Anticoagulants (DOACs), accounting for
115 (70.1%) prescriptions. Atrial fibrillation (AF) was the
most frequent indication in 119 patients (72.5%), Table 2.
For those taking Vitamin K antagonists (VKAs), the
mean International normalised ratio (INR) on admission
was 4.0 (SD 3.21). All patients admitted to the ICU on
anticoagulants were switched to low molecular weight
heparin (LMWH) therapy. At discharge, five patients
previously on warfarin were switched to either a DOAC
or LMWH.
Acute kidney injury
AKI was seen in 39 patients (23.8%) who were on antic-
oagulation which was higher than those not taking anti-
coagulants 171 (19.7%) but this difference was not
statistically significant (p = 0.278), Table 3. There was no
difference in severity of AKI between the groups with a
similar proportion of those who developed AKI experi-
encing stage 3 AKI; 19 (48.7%) of those on anticoagula-
tion and 73 (42.7%) of those not (p = 0.783), Table 4.
Fifty-nine percent of patients on anticoagulants had a
community acquired AKI as did 59% of those not antic-
oagulated. The median time to development of AKI
from COVID positive PCR result was 0 days (IQR − 2.5-
2.5) in the anticoagulated group and − 1 days (IQR − 1-1)
in the non-anticoagulated cohort. Renal replacement
therapy requirement was not different between groups
with 2 (1.2%) patients on anticoagulants versus 30 (3.5%)
(p = 0.204). Seventeen patients were deemed to have AKI
criteria without a baseline creatinine available, eight of
them required renal replacement therapy as per KDIGO
criteria and the remaining nine were deemed to have
clinical AKI based on consecutive review of creatinine
results.
Anticoagulation was not found to be a factor associ-
ated with AKI in multivariate analysis (OR 1.02 (0.60–
1.68, p = 0.952)). Factors that were linked with AKI were
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pre-existing renal disease (OR 2.31 (1.42–3.72, p =
0.001)), HTN OR 1.61 (1.07–2.46, p = 0.024) and male
sex (OR 1.65 (1.11–2.49, p = 0.015)), Table 5.
Survival
Overall 326 (31.6%) patients with a diagnosis of COVID-
19 died following hospital admission, 36 of these deaths
occurred following admission in the community. Mortal-
ity was higher in the anticoagulant therapy cohort with
66 (40.2%) of patients dying compared to 260 (30%; p =
0.012). The 30 day mortality was also higher in those
taking anticoagulants 34.8% versus those not previously
taking them 25.5% (p = 0.018), Table 3. If looking at
mortality specifically in patients with AKI there was no
difference between those on anticoagulation and those
not anticoagulated, p = 0.741 Table 4.
Compared to those not taking anticoagulants signifi-
cantly fewer patients on anticoagulants went to ICU 14
(8.5%) versus 151 (17.4%) (p = 0.006), Table 3. Of those
that were admitted to ICU, a much smaller proportion
of anticoagulated patients received mechanical ventila-
tion (p = 0.009). Patients on anticoagulants who were ad-
mitted to the ITU had a higher mortality than those
who weren’t previously anticoagulated (p = 0.042).
Across the whole study population, a multivariable cox
proportional hazards regression did not find anticoagula-
tion to have any impact upon overall survival HR 0.84
(CI 0.63–1.12, p = 0.283), supplementary Figure 1, and in




N 1032 868 164
Age 71 (56–83) 68 (54–82) 80 (70–85) < 0.001
Sex Male 569 (55.1) 485 (55.9) 84 (51.2) 0.311
Ethnicity White 725 (70.3) 586 (67.6) 139 (84.8) < 0.001
Asian 116 (11.3) 106 (12.2) 10 (6.1)
Black 94 (9.1) 88 (10.1) 6 (3.7)
Mixed 14 (1.4) 14 (1.6) 0 (0.0)
Other 28 (2.7) 28 (3.2) 0 (0.0)
Unknown 54 (5.2) 45 (5.2) 9 (5.5)
CCI Score 1 (0–2) 1 (0–2) 2 (1–3) < 0.001
Myocardial Infarction 83 (8.9) 61 (7.8) 22 (14.3) 0.015
Congestive Heart Failure 129 (13.8) 77 (9.9) 52 (33.8) < 0.001
Peripheral Vascular Disease 64 (6.9) 50 (6.4) 14 (9.1) 0.304
Cerebrovascular disease 45 (4.8) 38 (4.9) 7 (4.5) 1.000
Dementia 157 (16.8) 128 (16.4) 29 (18.8) 0.538
COPD 259 (27.7) 212 (27.2) 47 (30.5) 0.455
Rheumatoid Disease 23 (2.5) 16 (2.1) 7 (4.5) 0.123
Peptic Ulcer Disease 9 (1.0) 8 (1.0) 1 (0.6) 1.000
Mild Liver Disease 30 (3.2) 30 (3.8) 0 (0.0) 0.026
Diabetes without complications 237 (25.4) 191 (24.5) 46 (29.9) 0.193
Diabetes with complications 36 (3.9) 29 (3.7) 7 (4.5) 0.796
Hemi or Paraplegia 17 (1.8) 12 (1.5) 5 (3.2) 0.263
Renal Disease 144 (15.4) 109 (14.0) 35 (22.7) 0.009
Mod/Severe Liver Disease 12 (1.3) 12 (1.5) 0 (0.0) 0.247
Cancer 72 (7.7) 51 (6.5) 21 (13.6) 0.004
Metastatic cancer 24 (2.6) 14 (1.8) 10 (6.5) 0.002
AIDS 1 (0.1) 1 (0.1) 0 (0.0) 1.000
Hypertension 457 (44.3) 372 (42.9) 85 (51.8) 0.042
All results given in n (%) and median (IQR). Comorbidities based on ICD10 codes. CCI score Charlson Co-morbid Index score, COPD Chronic obstructive pulmonary
disease. Renal disease defined as Charlson Co-morbid Index (renal transplant, uraemia or serum creatinine >265micromol/)
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univariable analysis it was not an independent factor for
mortality HR 1.27 (CI 0.97–1.67; p = 0.081), supplemen-
tary Table 2. Factors from this analysis that were associ-
ated with mortality included AKI, age, diabetes, cancer
and heart failure, supplementary Figure 1.
Discussion
This retrospective, single-centre study found that pre-
existing therapeutic anticoagulation had no impact on
the risk of developing AKI or reducing its severity in
hospitalised patients with COVID-19. AKI was likely to
be present on admission. This is the first study we are
aware of to examine the effects of chronic anticoagula-
tion on COVID-19 related AKI.
The findings of this study would suggest that renal
microvascular thrombosis is unlikely to play a significant
role in COVID-19 related AKI. Early histopathological
analysis from Wuhan, China identified segmental fibrin
thrombi in glomerular loops associated with endothelial
injury and this was proposed as a contributing factor to
COVID-19 related AKI [19]. However, in this analysis,
not all patients displayed signs of kidney injury evi-
denced by raised creatinine. Further autopsy series in-
cluding a report from New York also identified platelet
rich fibrin microthrombi in peritubular capillaries and
venules in kidney tissues from all seven patients studied
[20, 21, 25]. There have also been suggestions that the
intricate link between the immune system and coagula-
tion pathways with microvascular endothelial injury and
hypercoagulability may exacerbate the risk of developing
acute tubular necrosis (ATN) [16]. A group looking at
12 renal biopsies with some degree of ATN showed no
evidence of thrombotic microangiopathy or vascular/ca-
pillary thrombi [26]. As more biopsy studies have been
published various pathologies have been seen including
collapsing glomerulopathy [27] and acute tubular injury
(ATI) which is the predominant finding in numerous
case series [19, 26, 28, 29]. ATI is likely multifactorial
due to sepsis, hypoxia, multiorgan complications and
rhabdomyolysis [29, 30]. The kidney has also been iden-
tified as being a target for SARS-CoV-2 via its ACE2
protein expressed on cells of the proximal tubule sup-
porting the potential for direct virus-mediated injury
[16]. Standard AKI risk factors are still implicated [16,
30, 31] and we found this in our population with signifi-
cantly more patients developing AKI that had pre-
existing renal disease, hypertension, diabetes and periph-
eral vascular disease which was also seen in another
publication [17]. Consideration of these risk factors need
to be undertaken to identify those patients susceptible to
AKI early in the disease course to try and minimise the
risk of developing AKI or its progression [30].
Stage 3 AKI was seen in 12% of all patients taking
anticoagulation and this finding is important to highlight
the need to review the suitability of the anticoagulant
depending on the patient’s condition [30]. Russo et al.
found that COVID-19 patients with AKI had a higher
risk of death from bleeding compared to the rest of the
study population and postulated this may have been re-
lated to an overdose of anticoagulants [32]. In patients
with COVID-19 and AKI stage 3, LMWH dosed as per
local protocols for renal impairment with anti-Xa moni-
toring should be preferred due to the DOACs’ reliance
on renal excretion and the variability of INR seen with
vitamin K antagonists (VKAs) [33, 34]. Supratherapeutic
INRs were seen in our patients at admission similar to a
study from Kings College, London which also noted high
INRs (INR > 8) mostly relating to the antimicrobial ther-
apy used to treat COVID-19 pneumonia [35]. Patients
chronically anticoagulated have been recommended to
switch to DOACs, if appropriate, during the pandemic
with less monitoring required than VKAs and this was
seen in a proportion of our patients at discharge [36].
However a recent Medicines Health Regulatory Author-
ity (MHRA) alert has highlighted an increase in reported









Metallic heart valve 2 (1.2)
LV thrombus 2(1.2)
VKA vitamin K antagonist, DOAC Direct acting oral anticoagulant, LMWH Low
molecular weight heparin, AF Atrial Fibrillation, VTE venous thromboembolism,
LV left ventricular
Table 3 Outcomes of all patients and stratified for those who
were taking anticoagulation or not anticoagulated
Overall Anticoagulation p-value
No Yes
n 1032 868 164
Died (%) 326 (31.6) 260 (30.0) 66 (40.2) 0.012
30-day mortality (%) 278 (26.9) 221 (25.5) 57 (34.8) 0.018
Readmit within 30 days (%) 86 (8.3) 69 (7.9) 17 (10.4) 0.383
Acute Kidney Injury 210 (20.3) 171 (19.7) 39 (23.8) 0.278
RRT (%) 32 (3.1) 30 (3.5) 2 (1.2) 0.204
Went to Critical care (%) 165 (16.0) 151 (17.4) 14 (8.5) 0.006
Died in Critical care (%) 59 (35.8) 50 (33.1) 9 (64.3) 0.042
Ventilation (%) 124 (75.2) 118 (78.1) 6 (42.9) 0.009
Values reported as n (%). RRT – renal replacement therapy
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major bleeding episodes with DOACs [37]. Due to po-
tential interactions with the COVID-19 trial medication
lopinavir/ritonavir [38] or macrolide antimicrobial ther-
apy used for pneumonia, along with high rates of AKI
associated with COVID-19 extra vigilance is required
when using these drugs to ensure the dose is appropriate
and any additional therapies are suitable in combination.
We found that significantly fewer patients taking anti-
coagulant therapy were admitted to the ICU and they
were less likely to receive mechanical ventilation than
those not anticoagulated. Our findings could be ex-
plained by agreed limitations of care in the anticoagu-
lated population due to pre-existing co-morbidities,
including metastatic cancer, and advanced age. Both of
these are also likely to impact on ICU survival. All of the
anticoagulated patients who became critically ill and
were admitted to ICU were switched to therapeutic
LMWH [39]. Additional benefits of LMWH in severe
COVID-19 disease have been described with a systematic
review concluding that heparin can decrease levels of in-
flammatory biomarkers [40]. Numerous mechanisms of
how heparins do this are described in the literature to in-
clude binding to and neutralisation of cytokines, interfer-
ence with leukocyte trafficking, reducing viral cellular
Table 4 Outcomes for patients with AKI stratified depending on whether they took anticoagulation or not
Overall-AKI Not anticoagulated-AKI Anticoagulated-AKI p-value
n 210 171 39
Died (%) 110 (52.4) 91 (53.2) 19 (48.7) 0.741
30-day mortality (%) 97 (46.2) 80 (46.8) 17 (43.6) 0.855
Readmit within 30 days (%) 13 (6.2) 10 (5.8) 3 (7.7) 0.95
Time to AKI from admission, days 0.00 (0.00–4.00) 0 (0.00–4.00) 1.00 (0.00–4.00) 0.966
Time to AKI from COVID diagnosis, days −1.00 (1.00–2.00) −1.00 (− 1.00–1.00) 0 (−2.50–2.50) 0.977
Initial AKI stage 1 123 (58.6) 99 (57.9) 24 (61.5) 0.380
2 37 (17.6) 33 (19.3) 4 (10.3)
3 50 (23.8) 39 (22.8) 11 (28.2)
Peak AKI stage 1 75 (35.7) 62 (36.3) 13 (33.3) 0.783
2 43 (20.5) 36 (21.1) 7 (17.9)
3 92 (43.8) 73 (42.7) 19 (48.7)
Day zero Sodium mmol/L 138.00 (133.00–142.00) 138.00 (133.00–142.00) 138.00 (134.50–142.50) 0.758
Peak Urea mmol/L 18.40 (12.80–27.30) 18.25 (12.43–26.98) 18.60 (14.10–29.05) 0.591
Creatinine μmol/L 189.00 (136.00–305.00) 187.00 (135.25–311.50) 191.00 (143.50–260.50) 0.831
CRP nmol/L 208.00 (107.00–312.00) 231.00 (110.25–317.75) 169.00 (94.50–218.50) 0.054
Minimum Haemoglobin g/L 96.00 (76.00–117.00) 96.00 (74.25–116.75) 97.00 (86.00–124.50) 0.36
Lymphocytes 109/L 0.64 (0.41–0.89) 0.64 (0.41–0.95) 0.63 (0.47–0.86) 0.941
Went to critical care 73 (34.8) 65 (38.0) 8 (20.5) 0.06
Died in critical care (%) 38 (52.1) 33 (50.8) 5 (62.5) 0.801
Ventilation (%) 63 (86.3) 59 (90.8) 4 (50.0) 0.009
Values reported as n (%) or median (IQR 25th–75th centile)
Table 5 Logistic regression for the development of AKI
Dependent: AKI OR (multivariable)
Age 1.00 (0.99–1.02, p = 0.794)
Sex M 1.65 (1.11–2.49, p = 0.015)
Ethnicity Asian 0.69 (0.31–1.42, p = 0.335)
Black 1.33 (0.70–2.45, p = 0.362)
Mixed 0.47 (0.02–3.15, p = 0.512)
Other 0.33 (0.02–1.76, p = 0.294)
Unknown 1.14 (0.42–2.76, p = 0.775)
Anticoagulation 1.02 (0.60–1.68, p = 0.952)
Hypertension 1.61 (1.07–2.46, p = 0.024)
Diabetes with complications 2.27 (0.93–5.40, p = 0.065)
Renal disease 2.31 (1.42–3.72, p = 0.001)
Cancer 1.57 (0.77–3.11, p = 0.203)
Metastatic cancer 1.45 (0.44–4.31, p = 0.522)
Day zeroa Sodium 1.04 (1.01–1.07, p = 0.015)
CRP 1.00 (1.00–1.01, p = 0.003)
EWS 1.11 (1.00–1.23, p = 0.046)
Number in dataframe = 1032, Number in model = 785, Missing = 247, AIC =
709.2, C-statistic = 0.708, H&L = Chi-sq(8) 4.76 (p = 0.783)
Multivariable models adjusted by demographics and variables showing
significance at univariable analysis (Univariate analysis is found in
Supplementary Table 1)
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entry, and neutralisation of extracellular cytotoxic histones
which can cause endothelial damage [41].
The patients chronically anticoagulated had a higher
co-morbid burden with an increased prevalence of heart
failure, renal disease and hypertension compared to
those not taking anticoagulation on admission (p < 0.05).
Anticoagulated individuals were also of advanced age
(80 vs 68 years) which makes it difficult to draw conclu-
sions on overall survival between the groups. These are
known risk factors for COVID-19 related mortality [42].
Recently a study carried out across the UK by the Inter-
national Severe Acute Respiratory and emerging Infec-
tions Consortium Coronavirus Clinical Characterisation
Consortium (ISARIC-4C) developed a risk stratification
score for COVID-19 mortality where increasing age,
multiple co-morbidities and urea > 14 mmol/L are some
of the major contributing factors to mortality [43]. Other
studies looking at the impact of anticoagulation on sur-
vival such as Tremblay et al. did not find any improve-
ments in overall survival of those therapeutically
anticoagulated [44]. This continues to support current
recommendations that therapeutic LMWH should not
be used for primary prophylaxis of VTE events without
further supporting evidence [45]. In contrast to these
findings, a study by Paranjpe et al. found patients initi-
ated on therapeutic dose anticoagulation in the hospital
had improved survival from COVID-19 compared to
those receiving prophylactic or none [46], although this
study lacked information on patient demographics and
reasons for initiating anticoagulation. Another study
found that pre-existing anticoagulation was protective
against the development of embolic events in COVID-19
patients [47] and this would seem logical given the find-
ing that the thrombotic process had started prior to ad-
mission with 50% of patients being diagnosed with VTE
within 24 h of hospitalisation [8]. The observational na-
ture of these studies re-iterates the need for randomised
controlled trials. The international REMAP-CAP trial
assessing the impact of therapeutic anticoagulation on
survival of patients with severe COVID-19 disease ad-
mitted to the ICU has been halted due to futility of
treatment with an increase in major bleeding. However,
this study continues to examine the effect of therapeutic
anticoagulation in those defined to have moderate
COVID-19 infection [48].
It could be inferred that patients taking chronic antic-
oagulation would be at an increased risk of developing
thromboembolic events with more cancer and metastatic
cancer and potential for acquired thrombophilia. With
similar rates of AKI between those on chronic anticoa-
gulation and those not anticoagulated it could be pos-
sible that therapeutic anticoagulation provides some
protection against AKI development however rando-
mised controlled trials would be needed to confirm this.
There are limitations to this single-centre observa-
tional study which include the inability to collect data
on major bleeding and VTE events. With the high mor-
tality in this study, especially in those already taking
anticoagulant therapy, and low ICU admission rates this
suggests that a high number of patients had limitations
of care in place which may have excluded investigations
for VTE. Also, if patients in this group were critically-ill,
imaging studies may not have been performed. Early on
in the course of COVID-19, the relevance of D-dimer
was not well defined [4] and was not routine in our
practice. Therefore, we do not have a complete dataset
for D-dimer comparison of those anticoagulated and
not. We did not include data on interventions of those
hospitalised which may have had an impact on outcomes
(e.g. those on the RECOVERY trial randomised to dexa-
methasone). It has not been possible to determine the
cause of death for patients aside from that patients died
whilst being treated for COVID-19.
Conclusion
This study shows that chronic anticoagulation does not
reduce the risk of developing AKI with COVID-19 or re-
duce the severity of AKI including requirement for RRT.
These findings would suggest that AKI in COVID-19 is
unlikely to be thrombotic in aetiology. COVID-19 re-
lated AKI is likely to be multifactorial and early detec-
tion and management is essential. RCTs are currently
underway to assess whether there is a specific group of
patients that therapeutic anticoagulation may provide
benefit and findings from RCTs will be needed to con-
clusively determine the ineffectiveness of anticoagulation
in preventing AKI. For patients on chronic anticoagula-
tion the choice of therapy must depend on the patients’
current condition and may need to be adjusted based on
development of AKI or initiation of interacting drugs.
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